Report
Pharmaceuticals: Read across from Q2 earnings in the US over Europe
PharmaceuticalsRead across from Q2 earnings in the US over Europe
Yesterday two US large cap healthcare companies, namely Biogen and Lilly, released their Q2 earnings numbers and beat consensus estimates, resulting into stock price increases by 4 to 5%. And from their operational performance, we see several very interesting read across to make, for the MS market and from a collaboration agreement with Roche on one side, for the diabetes market and for some oncology drugs on the other side. All in all, this is encouraging for the upcoming season of Q2 earnings in Europe. We confirm our more optimistic outlook for the segment for H2 2018.
Provider
Bryan Garnier
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Eric Le Berrigaud
Other Reports from Bryan Garnier
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.